Contract research, development, and manufacturing organization Aragen has secured a $100 million investment from private equity firm Quadria Capital. This investment will result in Quadria acquiring a minority stake in the company, valuing Aragen at approximately $1.4 billion.

The deal is structured primarily as a fresh capital infusion, with a smaller portion coming from the sale of shares by existing investors, according to a company statement released on Monday.

The funding aims to drive Aragen’s strategic growth by enhancing its capabilities and expanding its infrastructure. This expansion will position the company to better meet the rising demand for outsourcing services from pharmaceutical and biotech innovators in key markets like the United States and Europe.

Quadria’s investment marks its entry as Aragen's second strategic investor, joining Goldman Sachs in supporting the company’s growth journey.

Aragen’s CEO, Manni Kantipudi, described the investment as a pivotal step in scaling the company’s operations to address the evolving needs of the life sciences market.

He highlighted that the expanded capabilities will not only strengthen the firm’s integrated discovery and manufacturing services but also enable customers to accelerate the development and commercialization of their products more efficiently.

Quadria’s backing further reinforces Aragen's position as a global partner for research and manufacturing solutions, catering to a rapidly growing demand for outsourced drug development services. This partnership aligns with broader industry trends emphasizing innovation, speed to market, and comprehensive service offerings across the pharmaceutical value chain.